Targeting cancer stem-like cells of castration-resistant prostate cancer through combinatorial inhibition of MET/nuclear MET and β-Catenin pathways: potential therapeutic intellectual property in prostate cancer treatment

Xie, Yingqiu (PI)
Fan, Haiyan (CoI)
Dukenbayev, Kanat, (CoI)
Chen, Zhenbang (Other Faculty/Researcher)

Project: Research project

Call title (Call ID)

Faculty Development Competitive Research Grant Program 2019-2021

Project Description

Our goal is to determine whether the Crizotinib and iCRT3 combination enhances the anti-cancer effects of either Crizotinib or iCRT3 alone in human CRPC cells by targeting cancer stem-like cells and to define the mechanism by which combinatorial drugs inhibited nuclear MET/β-Catenin/ AR and novel signaling in human CRPC cells.

Short title	Targeting prostate cancer stem cell
Acronym	Prostate cancer drug target
Status	Active
Effective start/end date	1/31/19 → 12/31/21

View all

View less

Fingerprint

Intellectual Property

Catenins

Neoplastic Stem Cells

Castration

Prostatic Neoplasms

Therapeutics

Pharmaceutical Preparations

Neoplasms

crizotinib

Keywords

Prostate cancer
Experimental therapy